Fenfluramine
Active ingredient · 2 therapeutic classes
Sold as Fintepla
- Drug class
- Centrally Acting Antiobesity Products
- Availability
- See label
- Markets covered
- 2
- Products on record
- 2
Overview
Fenfluramine is an active pharmaceutical ingredient in the Centrally Acting Antiobesity Products group (A08AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | May 15, 2026 |
| EU European Union | EMA | 1 | May 7, 2026 |
GBUnited Kingdom· MHRA
1 product
Uses
Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
How to take
EUEuropean Union· EMA
1 product
Uses
Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox- Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
How to take
Drug interactions
Known interactions involving Fenfluramine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 271. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB000390804 · revised May 15, 2026
- [2]European Medicines Agency · EMEA/H/C/003933 · revised May 7, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.